Literature DB >> 368965

Treatment of herpes zoster with idoxuridine ointment, including a multivariate analysis of symptoms and signs.

K E Wildenhoff, J Ipsen, V Esmann, J Ingemann-Jensen, J H Poulsen.   

Abstract

A double-blind, random selection comparison was made of the therapeutic effects in acute herpes zoster of (A) 40% idoxuridine (IDU) dissolved in dimethyl sulphoxide (DMSO), or one of the following ointments: (B) a basis of polyethylene glycol, (C) a basis with 60% DMSO, (D) a basis with 5% IDU and 60% DMSO, and (E) a basis with 40% IDU and 60% DMSO. Each group comprised 20 patients. The patients were evaluated daily until skin healing and then at 1,3, and 6 months by registering 4 neurological signs, 5 clinical evaluations of skin pathology and 4 photographic evaluations of the skin lesions. A 'profile' of the effect of each treatment was computed by calculating normalized means for each of the 13 variables. A non-random distribution of the clinical and photographic variables indicated a statistically significant, but small therapeutic effect of treatment A on skin healing, whereas no convincing effect on pain or sensitivity disturbances was established. Treatments B-E were without positive effects. The information given by the highly interdependent variables were computed for each variable and for groups of variables after appropriate scoring. It was found that the photographic evaluation contributed evidence independent of the clinical evaluation of skin pathology. A multiple correlation analysis revealed that age was positively correlated to the duration of pain and to delayed healing, that rapid healing was intimately connected to no or short-lived pain, and surprisingly that zoster in the trigeminal area healed faster than in other locations without being correlated to less pain. Treatment A must necessarily be reevaluated taking into account proper controls as well as age and affected dermatomes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 368965     DOI: 10.3109/inf.1979.11.issue-1.01

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  11 in total

1.  Are current therapies useful for the prevention of postherpetic neuralgia? A critical analysis of the literature.

Authors:  K E Schmader; S Studenski
Journal:  J Gen Intern Med       Date:  1989 Mar-Apr       Impact factor: 5.128

2.  The enigma of herpes stromal disease.

Authors:  J McGill
Journal:  Br J Ophthalmol       Date:  1987-02       Impact factor: 4.638

Review 3.  Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials.

Authors:  T Lancaster; C Silagy; S Gray
Journal:  Br J Gen Pract       Date:  1995-01       Impact factor: 5.386

4.  Different seroprevalences of antibodies against Neisseria meningitidis serogroup A and Haemophilus influenzae type b in Sudanese and Swedish children.

Authors:  M A Salih; H Fredlund; S Hugosson; L Bodin; P Olcén
Journal:  Epidemiol Infect       Date:  1993-04       Impact factor: 2.451

5.  Limited value of acyclovir in the treatment of uncomplicated herpes zoster: a placebo-controlled study.

Authors:  P J van den Broek; J W van der Meer; J D Mulder; J Versteeg; H Mattie
Journal:  Infection       Date:  1984 Sep-Oct       Impact factor: 3.553

Review 6.  Antiviral therapy of acute herpes zoster in older patients.

Authors:  K Herne; R Cirelli; P Lee; S K Tyring
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

7.  [Pain therapy in herpes zoster and post-zoster neuralgia.].

Authors:  T Zenz; M Zenz; M Tryba
Journal:  Schmerz       Date:  1994-03       Impact factor: 1.107

8.  Oral acyclovir for acute herpes zoster infections in immune-competent adults.

Authors:  M J Wood; M W McKendrick; J I McGill
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 9.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

Review 10.  Recognition and treatment of shingles.

Authors:  A F Nikkels; G E Piérard
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.